Get the Stockscreener App
4.21
1.20%
0.05
Pre-market:
4.34
0.13
+3.09%
Whitehawk Therapeutics Inc stock is traded at $4.21, with a volume of 112.59K.
It is up +1.20% in the last 24 hours and up +19.94% over the past month.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
See More
Previous Close:
$4.16
Open:
$4.19
24h Volume:
112.59K
Relative Volume:
0.62
Market Cap:
$208.09M
Revenue:
$7.15M
Net Income/Loss:
$-20.60M
P/E Ratio:
8.8706
EPS:
0.4746
Net Cash Flow:
$-97.99M
1W Performance:
+1.94%
1M Performance:
+19.94%
6M Performance:
+87.11%
1Y Performance:
+161.49%
1-Day Range:
$4.12
$4.28
1-Week Range:
$3.77
$4.33
52-Week Range:
$1.53
$4.4799
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
4.21 | 208.09M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
The sustainable advantages Whitehawk Therapeutics (WHWK) is developing (Eye on Rally) 2026-05-05Hot Stocks - Newser
Whitehawk Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Whitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38 - MSN
Whitehawk Therapeutics (WHWK) price target increased by 13.33% to 5.78 - MSN
[ARS] Whitehawk Therapeutics, Inc. SEC Filing - Stock Titan
Whitehawk Therapeutics (NASDAQ: WHWK) details 2026 virtual shareholder meeting - Stock Titan
ABG Innovation Capital Partners III GP Ltd's Whitehawk Therapeutics Inc(WHWK) Holding History - GuruFocus
WHWK Whitehawk Therapeutics falls 3.36% as Q4 2025 EPS misses estimates by a wide 116.4 percent margin.Collaborative Trading Signals - Newser
Whitehawk jumps as Citizens issues outperform rating ahead of trial data - MSN
Oppenheimer Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $6 - Moomoo
WHWK Whitehawk Therapeutics posts wider than projected Q4 2025 loss, pushing its share price down 3.36% today.Stock Market Community - Newser
Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says - Moomoo
H.C. Wainwright Maintains Whitehawk Therapeutics(WHWK.US) With Hold Rating - Moomoo
Whitehawk Therapeutics (WHWK) Unveils New Preclinical Data at AA - GuruFocus
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 - InsideNoVa.com
What is driving sentiment for Whitehawk Therapeutics (WHWK) stock (On the Radar) 2026-04-18Trending Entry Points - Xã Thanh Hà
Whitehawk Therapeutics CFO sells $882k in stock - Investing.com
Whitehawk Therapeutics CFO sells $882k in stock By Investing.com - Investing.com Australia
Whitehawk Therapeutics Chief Financial Officer Sold Shares Worth Over $882K - TradingView
Whitehawk Therapeutics (WHWK) CFO disposes shares in tax-related broker sales - Stock Titan
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series - The AI Journal
Whitehawk stock wins Outperform rating from Citizens (WHWK) - Seeking Alpha
WHWK Initiated Coverage by Citizens -- Rating Set to Market Outp - GuruFocus
Whitehawk Therapeutics stock initiated with outperform rating at Citizens By Investing.com - Investing.com South Africa
Whitehawk Therapeutics stock initiated with outperform rating at Citizens - Investing.com
Proposed resale lists 473,902 units; insider sold 2,594 shares (WHWK) - Stock Titan
Whitehawk Therapeutics officer Ball sells $427,860 in stock - Investing.com
Whitehawk Therapeutics officer Ball sells $427,860 in stock By Investing.com - Investing.com South Africa
Whitehawk Therapeutics (WHWK) officer sells 118,849 shares for RSU tax withholding - Stock Titan
WHWK Stock Price and Chart — NASDAQ:WHWK - TradingView
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks - Yahoo Finance
Whitehawk Therapeutics officer Ball sells $201k in stock By Investing.com - Investing.com South Africa
Whitehawk Therapeutics officer Ball sells $201k in stock - Investing.com
Whitehawk Therapeutics (WHWK) insider disposes 56,596 shares for tax withholding - Stock Titan
EV Market: Will Whitehawk Therapeutics Inc benefit from government policyWeekly Stock Report & Free Community Supported Trade Ideas - baoquankhu1.vn
WHWK SEC FilingsWhitehawk Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Trade Alert: President Of Whitehawk Therapeutics David Lennon Has Sold Stock - simplywall.st
Whitehawk Therapeutics CEO Lennon sells $49k in shares By Investing.com - Investing.com Australia
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):